

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virignia 22313-1450 www.uspto.gov

CONFIRMATION NO. ATTORNEY DOCKET NO. FILING DATE FIRST NAMED INVENTOR APPLICATION NO. 241/172 09/374,338 08/13/1999 NORBERT WINDHAB 3614 EXAMINER 04/21/2004 34263 7590 WESSENDORF, TERESA D O'MELVENY & MEYERS 114 PACIFICA, SUITE 100 ART UNIT PAPER NUMBER **IRVINE, CA 92618**

1639 DATE MAILED: 04/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

			Application No.		Applicant(s)	
Office Action Summary		09/374,338	3	WINDHAB ET AL.		
		Examiner		Art Unit		
		T. D. Wess		1639		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠	Responsive to communication(s) filed on <u>08 December 2003</u> .					
2a)⊠	This action is FINAL . 2b) ☐ This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-54,57 and 59-146 is/are pending in the application. 4a) Of the above claim(s) 1-54,57 and 59-137 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 138-146 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2)	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO- mation Disclosure Statement(s) (PTO-1449 or PT er No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:		O-152)	

Application/Control Number: 09/374,338

Art Unit: 1639

Status of Claims

Claims 1-54, 57 and 59-146 are pending.

Claims 1-54, 57 and 59-137 are withdrawn from consideration, as stated above.

Claims 138-146 are under examination.

Specification

In view of the amendments to the specification the objection to the specification has been overcome.

Claim Rejections - 35 USC § 112, first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 138-146 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for reasons advanced in the last Office action.

Application/Control Number: 09/374,338 Page 3

Art Unit: 1639

Response to Arguments

Applicants argue that the objectionable term "pharmaceutically acceptable compound" has been deleted and replaced with "biologically active compound".

In response, this amendment to the claim does not obviate the rejection, essentially for the same reasons as set forth in the last Office action. The terms do not appear to affect the step in a manipulative means. [Reciting the specific biologically active compound will obviate this rejection.]

Claim Rejections - 35 USC § 112, second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

New claims 138-146 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A). Claim 138 is indefinite as the steps are unclear as to whether a drug(preamble) or a biologically active molecule(body of the claim) is being determined. The step of "determining which locations on the array has the biologically active molecule bound to the binding structure" is indefinite. It is

Application/Control Number: 09/374,338 Page 4

Art Unit: 1639

unclear as to the necessity of this step. The biologically active molecule binds to the peptide binding structure and not to the array bound pRNA.

- B. Claims 139-140 are unclear and at odds with the specification. The specification recites that the peptide forming the binding structure are known. It appears that it is the biologically active molecule, which sequence needs to be determined that is unknown. An essential step is missing in the base claimed method.
- C. Claim 141 is unclear as to the binding of a second biologically active compound to an array. Furthermore, the relative term "second" is indefinite absent positive recitation of a first biologically active molecule. Cf. with the now cancelled claim 56.
- D. Claim 146 "the first biologically active compound" lacks antecedent basis of support from the base claim.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the

Page 5

art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 138-146 are rejected under 35 U.S.C. 103(a) as being unpatentable over applicants' disclosure of known prior art in view of Cubicciotti et al (US 6,287,765) for reasons set forth in the last Office action.

Response to Arguments

Applicants argue that Cubicciotti does not disclose the supramolecular complex. Applicants further argued that the examiner asserted that the elected species is free of prior art.

In response, attention is drawn to Cubicciotti et al at e.g., col. 24, Example 16 which discloses a supramolecular complex linked to an array with peptide-nucleic acid complex.

The indication that the elected species is free of prior art is relative to the original claims and not as amended.

No claim is allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 09/374,338

Art Unit: 1639

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

This application contains claims 1-54, 57 and 59-137 drawn to an invention that is nonelected. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. D. Wessendorf whose telephone number is (571) 272-0812. The examiner can normally be reached on Flexitime.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (571) 272-0812. The fax phone numbers for the

Page 7

Application/Control Number: 09/374,338

Art Unit: 1639

organization where this application or proceeding is assigned are (703) 308-7924 for regular communications and (703) 308-7924 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

T. D. Wessendorf Primary Examiner Art Unit 1639

tdw April 16, 2004